Selank
Recherche publiée et base de preuves
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the immunomodulatory tetrapeptide tuftsin, developed at the Institute of Molecular Genetics in Moscow. Proposed mechanisms include inhibition of enkephalin-degrading enzymes, allosteric modulation of GABA-A receptor signalling, and regulation of BDNF and inflammation-related gene expression. Human data consist of a small number of Russian comparative trials in generalised anxiety disorder and neurasthenia, one placebo-controlled resting-state fMRI study in healthy volunteers, and small Russian and Ukrainian studies in atopic dermatitis, post-COVID asthenia and adjustment disorder published in journals that PubMed does not index. Almost the entire literature originates from a small group of Russian laboratories, and independent Western replication is absent.
- Selank est un heptapeptide synthétique dérivé du peptide tuftsin.
- Des études chez des patients anxieux et des volontaires sains ont rapporté des effets sur l'activité cérébrale.
- Presque toutes les recherches viennent de laboratoires russes ; aucune réplication occidentale.
22 études · 3 depuis 2023 · plus récente 2026
- Études citées
- 22
- Publiées 2023+
- 3
- Article le plus récent
- 2026
- Dernière révision
- oct. 2026
Thèmes récurrents dans la littérature
- anxiolytic
- tuftsin analogue
- enkephalin-degrading enzyme inhibition
- GABAergic gene expression
- BDNF
- intranasal peptide
- neuroinflammation
- benzodiazepine-sparing
Identifiants du composé
- CAS
- 129954-34-3
- PubChem
- 11765600
Ce qu'est Selank, chimiquement.
- Formule moléculaire
- C33H57N11O9
- Masse moléculaire
- 751.9 g/mol
- Numéro CAS
- 129954-34-3
- PubChem CID
- 11765600
Selanc
Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.
22 études publiées.
Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.
- 01Clinique humaine2026
Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician Adjudication
Marwaha A, et al. · Preprints.org · retrospective electronic-health-record study (preprint, not peer reviewed) using LLM-curated clinical notes with physician adjudication; Selank use confirmed in 27 of 39 patients with note mentions, pooled Semax or Selank cohort n=49
Documented use of both peptides rose from 2024, most often for cognitive enhancement or mood, anxiety and stress support (28.6% each), with intranasal use common (37%) and stacking with other peptides in 33 patients (67%). Notes recorded patient-reported positive responses in 16 of 49 patients and safety concerns or adverse-event sentiments in 13 of 49; the authors state the study was not designed to evaluate effectiveness or harm.
Résultat de sécurité signalé. Manual review found isolated dyspnea, palpitations, flushing and emergency department visits during periods overlapping reported Semax or Selank use (n<11).
- 02Clinique humaine2025· Russian (English abstract)
Modulation of the Surgical Stress Response in the Early Postoperative Period After Radical Nephrectomy as the Core of the Nephroprotective Strategy
Shormanov IS, et al. · Innovacionnaâ medicina Kubani · controlled study, two groups of patients after radical nephrectomy, one also receiving Selank for 2 weeks after surgery
Patients given Selank had significantly better recovery of biogenic amine metabolism, psycho-emotional and vegetative-vascular disorders and glomerular filtration rate after surgery. The abstract gives no patient numbers.
- 03Clinique humaine2024· Russian (English abstract)
POST-COVID SYNDROME, POSSIBILITIES FOR THERAPY OF ASTHENIC DISORDERS WITH SELANK
Pogodina M, Nikiforova E · Vrach · controlled study, n=64 patients with asthenia, reduced performance and emotional disorders after COVID-19; neuroprotective complex plus intranasal Selank (n=32) vs neuroprotective complex alone (n=32), 30 days
The authors reported a good effect of Selank on asthenia and impaired mental performance, with parallel relief of anxiety and depressive symptoms. The abstract gives no between-group statistics.
- 04Clinique humaine2020
Functional Connectomic Approach to Studying Selank and Semax Effects
Panikratova YR, et al. · Doklady Biological Sciences · placebo-controlled resting-state fMRI, 52 healthy participants; Semax, Selank or placebo, scanned before and 5 and 20 min after administration
Group and condition differences were detected in functional connectivity between the right amygdala and right temporal/parahippocampal cortex. The authors described both shared and compound-specific connectivity effects for Selank and Semax.
- 05Clinique humaine2020· Russian (English abstract)
Possibilities of cognitive-affective disorders correction in patients with atopic dermatitis using selanc regulatory peptide
Kruglova LS, et al. · Kursk Scientific and Practical Bulletin “Man and His Health” · randomised controlled study, n=65 patients with atopic dermatitis; basic therapy vs basic therapy plus intranasal Selank for 14 days, assessed at 30 days, with 30 healthy people as reference
Personal and reactive anxiety fell 2.4-fold with Selank plus basic therapy versus 1.3- to 1.4-fold with basic therapy alone; alexithymia fell 1.2-fold and blood beta-endorphin rose 1.9-fold only in the Selank group. The quality-of-life index fell 1.7-fold with Selank versus 1.2-fold with basic therapy, which the authors described as improved quality of life.
- 06Clinique humaine2020· Russian (English abstract)
Effect of combined phototherapy and regulatory polypeptide selank on cytokine blood profile of patients with atopic dermatitis
Dontsova EV, et al. · Medicinskij alfavit · comparative four-arm study, n=124 patients with moderate atopic dermatitis (mean age 23.7): basic drug therapy, plus Selank, plus combined UV phototherapy, or Selank plus phototherapy plus basic therapy
Basic drug therapy had the least effect on blood IL-1β, IL-4, IL-10, IL-13 and IgE; adding Selank increased the anti-inflammatory effect, and Selank combined with UV phototherapy and basic therapy produced the most pronounced change (p<0.001 versus the monotherapy and basic-therapy groups).
- 07Clinique humaine2018
The effectiveness of selank in the treatment of adjustment disorder
Verbenko G, Verbenko V · PMGP · wait-list controlled study, n=30 patients with adjustment disorder in Ukraine; Selank for two weeks vs no treatment, two further weeks of follow-up
At the end of follow-up, PHQ scores were significantly lower in the Selank group than in wait-list controls for somatic symptoms (1.2 vs 3.6), nutritional problems (0.1 vs 3.4) and alcohol misuse (0.3 vs 1.5; p<0.05).
- 08Clinique humaine2015· Russian (English abstract)
[Optimization of the treatment of anxiety disorders with selank]
Medvedev VE, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · randomised controlled trial, n=70; phenazepam monotherapy (n=30) vs phenazepam plus selank (n=40) in anxiety-phobic, hypochondriac and somatoform disorders
Combined treatment reached the therapeutic HDRS effect earlier than phenazepam alone and was associated with fewer benzodiazepine-related adverse effects, including attention and memory impairment, sedation and asthenia. SF-36 quality-of-life scores favoured the combination arm.
- 09Clinique humaine2014· Russian (English abstract)
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
Medvedev VE, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · comparative clinical trial, n=60 patients with phobic-anxiety and somatoform disorders (ICD-10 F40.2-9, F41.1-9, F45.0-1)
The authors reported an anxiolytic effect with a mild nootropic component, persisting for approximately one week after the last dose. Quality-of-life ratings improved during treatment.
- 10Clinique humaine2008· Russian (English abstract)
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
Zozulia AA, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · randomised comparative trial, n=62 patients with generalised anxiety disorder or neurasthenia; selank (n=30) vs medazepam (n=32)
Anxiolytic effects of selank and medazepam were reported as similar on Hamilton, Zung and CGI scales, with additional antiasthenic and psychostimulant effects attributed to selank. Treatment was associated with an increase in leucine-enkephalin half-life in serum, which the authors linked to symptom change.
- 11Clinique humaine2008· Russian (English abstract)
[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]
Uchakina ON, et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · clinical study with in vitro component; patients with generalised anxiety disorder and neurasthenia treated for 14 days
Selank altered the serum Th1/Th2 cytokine balance in treated patients and suppressed IL-6 gene expression in peripheral blood cells from patients but not healthy controls in vitro.
- 12Animal in vivo2022
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Konstantinopolsky MA, Chernyakova IV, Kolik LG · Bulletin of Experimental Biology and Medicine · rat morphine withdrawal model
Selank reduced aversive behavioural signs of morphine withdrawal in rats. This is the most recent primary Selank research article indexed in PubMed.
- 13Animal in vivo2019
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
Kolik LG, et al. · Bulletin of Experimental Biology and Medicine · rats, ethanol-induced memory impairment; hippocampal and prefrontal cortex BDNF measurement
Selank attenuated ethanol-induced memory impairment in rats, an effect the authors associated with changes in BDNF content in the hippocampus and prefrontal cortex.
- 14Animal in vivo2017
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Kasian A, et al. · Behavioural Neurology · rats, unpredictable chronic mild stress paradigm, Selank with and without diazepam
Co-administration of Selank modified the anxiolytic effect of diazepam under chronic mild stress, consistent with the hypothesis of shared benzodiazepine-like mechanisms.
- 15Animal in vivo2016
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Volkova A, et al. · Frontiers in Pharmacology · rat frontal cortex, 84-gene neurotransmission qPCR panel at 1 h and 3 h after Selank or GABA (300 microg/kg)
Forty-five of 84 neurotransmission-related genes changed expression 1 h after administration and 22 at 3 h, with correlated changes between Selank and GABA. The authors proposed allosteric modulation of the GABAergic system as one possible mechanism.
- 16Animal in vivo2008
Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo
Inozemtseva LS, et al. · Doklady Biological Sciences · intranasal administration in rats, hippocampal BDNF expression
Intranasally administered Selank altered BDNF expression in the rat hippocampus, providing an early link between the peptide and neurotrophin signalling.
- 17In vitro2017
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Filatova E, et al. · Frontiers in Pharmacology · IMR-32 human neuroblastoma cell line
Selank changed expression of GABAergic neurotransmission genes in a neuronal cell line, with partial overlap to the profiles produced by GABA and olanzapine.
- 18In vitro2017
Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons
Povarov IS, et al. · Bulletin of Experimental Biology and Medicine · rat hippocampal slice electrophysiology, CA1 pyramidal neurons
Selank altered spontaneous synaptic activity in hippocampal CA1 neurons, providing direct electrophysiological evidence of an effect on hippocampal network signalling.
- 19In vitro2001
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity
Zozulya AA, et al. · Bulletin of Experimental Biology and Medicine · human plasma enzymology plus patient sampling in anxiety and phobic disorders (DSM-IV)
Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin with an IC50 of approximately 15 microM, more potently than bacitracin or puromycin. Patients with generalised anxiety showed shortened enkephalin half-life at baseline.
- 20Revue2021
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
Doyno CR, White CM · J Clin Pharmacol · narrative pharmacology review of GABAergic sedative-hypnotics (flunitrazepam, GHB, phenibut, Selank)
Selank and phenibut were described as poorly studied Russian drugs with GABAergic mechanisms sold to US consumers as dietary supplements, and the authors called for evaluation of abuse potential before public access.
- 21Revue2020
The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind
Vanhee C, et al. · Drug Testing and Analysis · analytical study of seized illicit pharmaceutical preparations
Selank and Semax were identified among cognitive-enhancing research peptides present in seized preparations, documenting non-prescription circulation of these compounds outside Russia.
- 22Revue2018
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
Vyunova TV, et al. · Protein and Peptide Letters · narrative review of molecular mechanisms
The review summarised proposed molecular targets of Selank, including enkephalinase inhibition, GABA-receptor system interaction and gene-expression effects, and noted that a specific receptor has not been identified.
Ce que ces preuves n'établissent pas.
No randomised, placebo-controlled Selank trial has been conducted or published outside Russia, no Phase III programme exists, and there are no primary Selank research articles indexed in PubMed after 2022. Pharmacokinetics, a defined molecular receptor, long-term safety and any effect on cognition in healthy adults remain unestablished.
Questions courantes sur la recherche.
- What is Selank?
Selank is a synthetic heptapeptide analogue of tuftsin, an immune-derived tetrapeptide, extended with a Pro-Gly-Pro sequence that slows enzymatic breakdown. It was developed at the Institute of Molecular Genetics in Moscow and is studied chiefly in anxiety and stress models.
- What does the research literature actually describe?
Preclinical work reports effects on GABAergic gene expression, on monoamine and enkephalin metabolism, and on behaviour in rodent stress models. A small Russian clinical literature examines intranasal courses against benzodiazepine comparators. None of this establishes an outcome in humans outside those study settings, and nothing here should be read as a claim about what the compound does for a person.
- How does Selank differ from Semax?
Both are Pro-Gly-Pro-stabilised Russian research heptapeptides, but their parent sequences differ. Selank derives from tuftsin and is studied in anxiety and stress models; Semax derives from ACTH(4-7) and is studied in neurotrophic and ischaemia models. The two are frequently co-studied, which is why they appear together in the literature.
Disponible dans notre catalogue
À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.